Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
6 hedge funds and large institutions have $135K invested in Genetic Technologies Ltd. in 2014 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
23% more capital invested
Capital invested by funds: $110K → $135K (+$25K)
40% less funds holding
Funds holding: 10 → 6 (-4)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$70.9K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$37.7K |
| 3 |
Jane Street
New York
|
+$11.5K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIM
Calvert Investment Management
Bethesda,
Maryland
|
-$11K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.89K |
| 4 |
Citigroup
New York
|
-$2K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $62K | +$70.9K | +908 | +504% |
|
|
VKH
2
Virtu KCG Holdings
New York
| $42K | +$37.7K | +483 | +190% |
|
|
3
Citadel Advisors
Miami,
Florida
| $8K | -$2.89K | -37 | -20% |
|
|
4
Ameriprise
Minneapolis,
Minnesota
| $8K | +$11.3K | +145 | +7,250% |
|
|
5
Jane Street
New York
| $8K | +$11.5K | +147 | New |
|
|
ARTA
6
A.R.T. Advisors
New York
| $7K | – | – | – |
|
|
CIM
7
Calvert Investment Management
Bethesda,
Maryland
| – | -$11K | -108 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$4K | -42 | Closed |
|
|
9
Citigroup
New York
| – | -$2K | -15 | Closed |
|
|
10
Group One Trading
Chicago,
Illinois
| – | -$1K | -10 | Closed |
|
GENE Hedge Fund Activity: Q3 2014 in Review
6 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q3 2014, worth a combined $135K — up 23% from $110K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GENE and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $70.9K. The largest seller was Calvert Investment Management, exiting entirely with an estimated $11K sold.
- 6 institutional investors held Genetic Technologies Ltd. (GENE) as of Q3 2014, down from 10 in Q2 2014.
- Funds reported $135K of Genetic Technologies Ltd. stock for Q3 2014, up 23% quarter-over-quarter.
- 1 fund opened new Genetic Technologies Ltd. positions in Q3 2014 and 4 closed out, a net change of -3 holders.
- The largest Genetic Technologies Ltd. buyer in Q3 2014 was Renaissance Technologies, an estimated $70.9K added.
- The largest Genetic Technologies Ltd. seller in Q3 2014 was Calvert Investment Management, an estimated $11K sold.
Based on aggregated 13F filings for Q3 2014.